Abstract
Introduction Metabolic syndrome (MetS) is important for public health; however, there are different ways to define it.
Objectives 1) to estimate the prevalence of MetS using three different definitions: the criteria of the International Diabetes Federation (IDF), the World Health Organization (WHO), and the National Cholesterol Education Program’s Adult Treatment Panel III (ATPIII), 2) to identify the factors associated with the presence of MetS according to each criterion, and 3) to evaluate the agreement between these three.
Materials and Methods A secondary and cross-sectional analysis of the database from the Life Stages Food and Nutrition Surveillance Survey (VIANEV) was conducted. For the definition of MetS, the aforementioned definitions were used. A multivariable Poisson regression analysis with robust variance and agreement was evaluated through the Kappa index.
Results According to ATPIII, IDF, and WHO, the prevalence of MetS was 42.60%, 46.78%, and 49.49%, respectively. The agreement between IDF with WHO and ATPIII criteria was 0.42 and 0.45, while for ATPIII and WHO it was 0.44. In general, the associated factors were identified as sex, marital status, age, region of residence, level of physical activity, smoking habit, and body mass index (BMI). However, the association of these varied according to the definition used.
Conclusion The prevalence of MetS varies significantly according to the criteria used. This was higher when the WHO definition was used compared to the others. Additionally, the associated factors varied according to the definition used, although a consistency was observed across all definitions with BMI.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study is self-financed.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used freely available data and in the public domain online, that were originally located at: http://iinei.inei.gob.pe/microdatos/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.